Home  /   Products  /   Cardiovascular  /   Valsartan, sacubitril (Uperio) 200 mg “102.8 mg + 97.2 mg” – [56 tablets]

Valsartan, sacubitril (Uperio) 200 mg “102.8 mg + 97.2 mg” – [56 tablets]

$178.02

For the treatment of chronic heart failure as a substitute for angiotensin-converting enzyme inhibitors (aceis) or angiotensin ii receptor antagonists (ara ii).

SKU: 63490 Category:

Description

Uperio Pharmacodynamics

Mechanism of Action

The action of uperio tablets is mediated by a new mechanism, involving simultaneous inhibition of neprilysin activity by sacubitrilat and blockade of angiotensin II receptors by valsartan.

Under the influence of sacubitrilat, there is an increase in neprilysin degradable peptides (such as natriuretic peptides), causing complementary cardiovascular and renal health effects in heart failure patients.

Natriuretic peptides activate guanylyl cyclase-conjugated receptors, leading to vasodilation, increased natriuresis and diuresis, enhanced renal function, and more.

Indications

Uperio tablets are indicated for the treatment of chronic heart failure (NYHA class II-IV) in patients with systolic dysfunction to decrease the risk of cardiovascular mortality and heart failure hospitalization.

They are used in combination therapy with other drugs as a substitute for angiotensin-converting enzyme inhibitors or angiotensin II receptor antagonists.

Contraindications

    • Hypersensitivity to sacubitril, valsartan, or other excipients
    • Concomitant use with ACE inhibitors within 36 hours of ACE withdrawal
    • History of angioedema with prior ACE inhibitor or ARB therapy

Dosage and Administration

    • Dosing of uperio tablets does not depend on food intake timing
    • The target daily dose is 200 mg (102.8 mg sacubitrilat + 97.2 mg valsartan) taken twice a day
    • Starting dose is 100 mg (51.4 mg sacubitrilat + 48.6 mg valsartan) twice daily, which can be doubled every 2-4 weeks

Patients in Special Categories

Patients with Impaired Renal Function: Dosage adjustments may be necessary for patients with mild to severe renal impairment. Caution is advised in patients with severe renal impairment due to limited data.

Patients with Hepatic Impairment: Dosage adjustments are recommended for patients with moderate hepatic impairment. Huperio is not recommended for use in patients with severe hepatic impairment.

Administration in Children and Adolescents: Uperio is not recommended for use in children under 18 years of age due to lack of data on safety and efficacy.

Use in Patients Over 65 Years of Age: No dose adjustment is required for patients over 65 years of age.

Note: This information is provided for educational purposes and is not a substitute for medical advice. Consult your healthcare professional before using any medication.


Valsartan: more than a decade of experience